Contact Us
Drug Search Results
More Filters [+]

Ripasudil

Alternative Names: ripasudil, k-321, k321, k 321, glanatec
Latest Update: 2024-11-05
Latest Update Note: Clinical Trial Update

Product Description

Ripasudil hydrochloride hydrate (Glanatec ophthalmic solution 0.4 %; hereafter referred to as ripasudil) is a small-molecule, Rho-associated kinase inhibitor developed by Kowa Company, Ltd. for the treatment of glaucoma and ocular hypertension.

Mechanisms of Action: ROCK Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Ocular,Ophthalmic

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: India | Japan | Korea | Malaysia | Singapore

Approved Indications: None

Known Adverse Events: None

Company: Kowa
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ripasudil

Countries in Clinic: Canada, Denmark, Germany, Puerto Rico, Spain, United Kingdom, United States

Active Clinical Trial Count: 7

Highest Development Phases

Phase 3: Blindness|Capsule Opacification|Cataract|Corneal Dystrophies, Hereditary|Corneal Edema|Corneal Endothelial Cell Loss|Diabetic Retinopathy|Fuchs' Endothelial Dystrophy

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
K-321-301

P3

Unknown Status

Diabetic Retinopathy

2025-08-30

RDMEK-01

P2

Recruiting

Fuchs' Endothelial Dystrophy

2025-02-01

FECD

P3

Recruiting

Corneal Dystrophies, Hereditary|Fuchs' Endothelial Dystrophy

2024-12-01

FECD

P3

Active, not recruiting

Fuchs' Endothelial Dystrophy|Cataract|Corneal Dystrophies, Hereditary

2024-10-01

Recent News Events

Date

Type

Title

04/30/2024

PubMed

 The Protective Effect of Rho-Associated Kinase Inhibitor Eye Drops (Ripasudil) on Corneal Endothelial Cells After Cataract Surgery: A Prospective Comparative Study.

04/10/2024

PubMed

 Axonal protection by combination of ripasudil and brimonidine with upregulation of p-AMPK in TNF-induced optic nerve degeneration.

02/20/2024

PubMed

 Evaluating the efficacy of Rho kinase inhibitor eye drops in the management of corneal edema: A single-center retrospective cohort study.

11/04/2021

News Article

 Aerie Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

10/12/2021

News Article

 Aerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japan

09/09/2021

News Article

 Retinopathy Of Prematurity (Ophthalmology) Drugs Pipeline Report 2021 - ResearchAndMarkets.com

07/27/2021

News Article

 Ocular Hypertension Market Insight, Epidemiology and Market Forecast Report 2021-2030 - ResearchAndMarkets.com

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions